Danapha Pharmaceutical JSC (HSTC:DAN) EBITDA Margin %: 0.00% (As of . 20)


HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
30 GF Score
Price ₫30,300.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC EBITDA Margin %?

Danapha Pharmaceutical JSC HSTC:DAN 30 EBITDA Margin % is 0.00% as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Danapha Pharmaceutical JSC ranks worse than 104711.94% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Danapha Pharmaceutical JSC's EBITDA for the six months ended in . 20 was ₫0.00 Mil. Danapha Pharmaceutical JSC's Revenue for the six months ended in . 20 was ₫0.00 Mil. Therefore, Danapha Pharmaceutical JSC's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Danapha Pharmaceutical JSC  (HSTC:DAN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Danapha Pharmaceutical JSC EBITDA Margin % Related Terms

Danapha Pharmaceutical JSC EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC EBITDA Margin % Chart

Danapha Pharmaceutical JSC Annual Data
Trend
EBITDA Margin %

Danapha Pharmaceutical JSC Semi-Annual Data
EBITDA Margin %

HSTC:DAN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Danapha Pharmaceutical JSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danapha Pharmaceutical JSC EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Danapha Pharmaceutical JSC's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Danapha Pharmaceutical JSC's EBITDA Margin % falls into.


HSTC:DAN
30GF Score
Danapha Pharmaceutical JSC HSTC:DAN
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danapha Pharmaceutical JSC EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Danapha Pharmaceutical JSC's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Danapha Pharmaceutical JSC's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Danapha Pharmaceutical JSC and its competitors. According to the industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is Danapha Pharmaceutical JSC's EBITDA Margin % too high?
Danapha Pharmaceutical JSC's current EBITDA Margin % is 0.00%. Based on the distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 955 companies for EBITDA Margin %. This places Danapha Pharmaceutical JSC in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Danapha Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danapha Pharmaceutical JSC's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Danapha Pharmaceutical JSC's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
30GF Score

Get the complete analysis for HSTC:DAN

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫30,300.00
Price